| 1. |
Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2021; 3: CD010383.
|
| 2. |
Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 2018; 29: i3-9.
|
| 3. |
Aw DC, Tan EH, Chin TM, et al. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia Pac J Clin Oncol 2018; 14: 23-31.
|
| 4. |
Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013; 13: 729-36.
|
| 5. |
Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol 2014; 21: 329-36.
DOI
PMID
|
| 6. |
Hu S, Dan W, Liu J, et al. The use of Traditional Chinese Medicine in relieving EGFR-TKI-associated diarrhea based on network pharmacology and data mining. Evid Based Complement Alternat Med 2021; 2021: 5530898.
|
| 7. |
Chinese Society of Lung Cancer CA-CA. EGFR-TKI ADR management Chinese expert consensus. Zhong Guo Fei Ai Za Zhi 2019; 22: 57-81.
|
| 8. |
Xu W, Han Q, Liang S, et al. Modified Shenlingbaizhu decoction reduces intestinal adenoma formation in adenomatous polyposis coli multiple intestinal neoplasia mice by suppression of hypoxia-inducible factor 1alpha-induced CD4+CD25+forkhead box P3 regulatory T cells. J Tradit Chin Med 2018; 38: 22-32.
|
| 9. |
Ji HJ, Kang N, Chen T, et al. Shen-ling-bai-zhu-san, a spleen-tonifying Chinese herbal formula, alleviates lactose-induced chronic diarrhea in rats. J Ethnopharmacol 2019; 231: 355-62.
|
| 10. |
Shen J, Zheng X, Zhang X, Yuan Y. Clinical study of Shen-Ling-Bai-Zhu powder applied to umbilical cord in treating chronic diarrhea of spleen-deficiency type in children. Asian J Surg 2022; 45: 1500-1.
|
| 11. |
Ma Q, Ouyang Y, Meng F, et al. A review of pharmacological and clinical studies on the application of Shenling Baizhu San in treatment of ulcerative colitis. J Ethnopharmacol 2019; 244: 112105.
|
| 12. |
Lai J, Jiang F, Zhuo X, et al. Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology. Chin Med 2022; 17: 140.
|
| 13. |
Association CM. Clinical practice guidelines for tumor. Beijing: People's Medical Publishing House, 2009: 83-6.
|
| 14. |
Kumar A, Kumar S, Gilja S, et al. Reconsidering the American Joint Committee on Cancer Eighth Edition TNM staging manual classifications for T2b and T 3 NSCLC. J Thorac Oncol 2021; 16: 1672-83.
|
| 15. |
Services USDoHaH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda: National Cancer Institute, 2017: 13-5.
|
| 16. |
Zheng X. Guidelines for the clinical use of new prescriptions of TCM. Beijing: China Medical Science and Technology Press, 2002: 51-3.
|
| 17. |
Zhou J. Practice of medical oncology treatment. Beijing: Beijing Science and Technology Press, 2010: 239-41.
|
| 18. |
Wang X, Yang Q, Zhou X, et al. Shenling Baizhu powder inhibits RV-SA11-induced inflammation and rotavirus enteritis via TLR4/MyD88/NF-kappa B signaling pathway. Front Pharmacol 2021; 12: 642685.
|
| 19. |
Friendlander AH, Ettinger RL. Karnofsky performance status scale. Spec Care Dentist 2009; 29: 147-8.
DOI
PMID
|
| 20. |
National Cancer Research and Control Office P, Association CA-C. Primary Bronchopulmonary Cancer. Beijing: Peking Union Medical College Press, 1990: 49-51.
|
| 21. |
China MoHotPsRo. Decree of the Ministry of Health of the People's Republic of China No. 81. 2011-05-04, cited 2011-05-24; Available from URL: https://www.gov.cn/flfg/2011-05/24/content_1870110.htm.
|
| 22. |
Aggarwal C. Targeted therapy for lung cancer: present and future. Ann Palliat Med 2014; 3: 229-35.
DOI
PMID
|
| 23. |
Liao BC, Lin CC, Lee JH, Yang JC. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer 2017; 110: 7-13.
|
| 24. |
Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phaseⅡextension component. J Clin Oncol 2017; 35: 1288-96.
|
| 25. |
Ding PN, Lord SJ, Gebski V, et al. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a Meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol 2017; 12: 633-43.
DOI
PMID
|
| 26. |
Chen P, Wang L, Liu B, et al. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a Meta-analysis. Eur J Clin Pharmacol 2011; 67: 235-43.
DOI
PMID
|
| 27. |
Jiao L, Xu J, Sun J, et al. Chinese herbal medicine combined with EGFR-TKI in EGFR mutation-positive advanced pulmonary adenocarcinoma (CATLA): a multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol 2019; 10: 732.
DOI
PMID
|
| 28. |
Tang M, Wang S, Zhao B, et al. Traditional Chinese Medicine prolongs progression-free survival and enhances therapeutic effects in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations. Med Sci Monit 2019; 25: 8430-7.
|
| 29. |
Liu ZL, Zhu WR, Zhou WC, et al. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and Meta-analysis. J Integr Med 2014; 12: 346-58.
|
| 30. |
Lyu C, Shi C, Li L, Wen X, Xian CJ. Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting. Curr Opin Support Palliat Care 2018; 12: 174-80.
|
| 31. |
Lyu W, Liu C, Ye C, et al. Structural modulation of gut microbiota during alleviation of antibiotic-associated diarrhea with herbal formula. Int J Biol Macromol 2017; 105: 1622-9.
DOI
PMID
|
)
